Related Experiment Video
Updated: Oct 21, 2025

05:57
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
4.5K
The Convalescent Plasma Craze! Where Does India Stand?
Arcot J Priyadarsini1, Kumar Karan1, Subramanian Arulselvi2
1Department of Transfusion Medicine, AIIMS, New Delhi, India.
Journal of Laboratory Physicians
|September 6, 2021
Summary
Convalescent plasma therapy, an ancient treatment, is being explored for COVID-19. This review discusses its pros, cons, and feasibility in India, a nation with a high number of coronavirus disease 2019 cases.
Area of Science:
- Infectious Diseases
- Immunology
- Hematology
Background:
- India ranks second globally in COVID-19 cases, necessitating diverse treatment strategies.
- The pandemic has revived interest in convalescent plasma therapy, a treatment modality with historical precedent.
- Developing nations like India face unique challenges in adopting novel medical interventions.
Purpose of the Study:
- To review the advantages and disadvantages of using convalescent plasma transfusion for treating COVID-19 patients.
- To assess the practical implementation and logistical hurdles of convalescent plasma therapy in the Indian context.
Main Methods:
- A comprehensive literature search was conducted using PubMed, Scopus, and Embase.
- Articles were selected to provide a balanced overview of convalescent plasma therapy.
- Expert opinion was incorporated regarding the feasibility in India.
Main Results:
- Convalescent plasma therapy offers potential benefits but also carries risks.
- Implementation in India requires addressing specific logistical and resource-related challenges.
- The review synthesizes existing knowledge and expert perspectives.
Conclusions:
- Convalescent plasma therapy is a viable, albeit challenging, option for COVID-19 treatment in India.
- Careful consideration of feasibility and logistics is crucial for successful implementation.
- Further research and standardized protocols are needed for widespread adoption.

